Cargando…

Is Lymphadenectomy Reasonable for Elderly Intrahepatic Cholangiocarcinoma Patients?

BACKGROUND: In this study, we aimed to determine the impact of lymphadenectomy (LND) on clinical outcomes in ICC patients aged ≥ 70 years. METHODS: Four hundred and three eligible patients diagnosed with ICC who underwent hepatectomy between 2004 and 2019 were enrolled in the Surveillance, Epidemiol...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Qianyi, Chen, Jianjun, Li, Kangde, Yang, Junxing, Luo, Xiaofeng, Cai, Qi, Lin, Weihong, Peng, Guanjing, Chen, Dexiong, Qin, Chunhong, He, Tao, Wang, Zhenlong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661814/
https://www.ncbi.nlm.nih.gov/pubmed/37783911
http://dx.doi.org/10.1007/s11605-023-05846-y
_version_ 1785138063968567296
author Lin, Qianyi
Chen, Jianjun
Li, Kangde
Yang, Junxing
Luo, Xiaofeng
Cai, Qi
Lin, Weihong
Peng, Guanjing
Chen, Dexiong
Qin, Chunhong
He, Tao
Wang, Zhenlong
author_facet Lin, Qianyi
Chen, Jianjun
Li, Kangde
Yang, Junxing
Luo, Xiaofeng
Cai, Qi
Lin, Weihong
Peng, Guanjing
Chen, Dexiong
Qin, Chunhong
He, Tao
Wang, Zhenlong
author_sort Lin, Qianyi
collection PubMed
description BACKGROUND: In this study, we aimed to determine the impact of lymphadenectomy (LND) on clinical outcomes in ICC patients aged ≥ 70 years. METHODS: Four hundred and three eligible patients diagnosed with ICC who underwent hepatectomy between 2004 and 2019 were enrolled in the Surveillance, Epidemiology, and End Results database. The impact of LND on perioperative mortality and overall survival (OS) as well as the optimal total number of lymph nodes examined (TNLE) was estimated. RESULTS: One hundred thirty-nine pairs of patients were matched by propensity score matching. Perioperative mortality was comparable between the LND and non-LND (nLND) groups (0.7% vs. 2.9%, P = 0.367). The median OS in the LND group was significantly longer (44 vs. 32 months, P = 0.045) and LND was identified as an independent protective factor for OS by multivariate analysis (HR 0.65, 95% CI 0.46–0.92, P = 0.014). Patients with the following characteristics were potential beneficiaries of LND: white, female, no/moderate fibrosis, tumor size > 5 cm, solitary tumor, and localized invasion (all P < 0.05). TNLE ≥ 6 had the greatest discriminatory power for identifying lymph node metastasis (area under the curve, 0.704, Youden index, 0.365, P = 0.002). Patients with pathologically confirmed lymph node metastasis are likely to benefit from adjuvant therapy (40 months vs. 4 months, P = 0.052). CONCLUSIONS: Advanced age (≥ 70 years) was not a contraindication for LND, which facilitates accurate nodal staging and guides postoperative management. Appropriately selected elderly populations could benefit from LND. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11605-023-05846-y.
format Online
Article
Text
id pubmed-10661814
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-106618142023-10-02 Is Lymphadenectomy Reasonable for Elderly Intrahepatic Cholangiocarcinoma Patients? Lin, Qianyi Chen, Jianjun Li, Kangde Yang, Junxing Luo, Xiaofeng Cai, Qi Lin, Weihong Peng, Guanjing Chen, Dexiong Qin, Chunhong He, Tao Wang, Zhenlong J Gastrointest Surg Original Article BACKGROUND: In this study, we aimed to determine the impact of lymphadenectomy (LND) on clinical outcomes in ICC patients aged ≥ 70 years. METHODS: Four hundred and three eligible patients diagnosed with ICC who underwent hepatectomy between 2004 and 2019 were enrolled in the Surveillance, Epidemiology, and End Results database. The impact of LND on perioperative mortality and overall survival (OS) as well as the optimal total number of lymph nodes examined (TNLE) was estimated. RESULTS: One hundred thirty-nine pairs of patients were matched by propensity score matching. Perioperative mortality was comparable between the LND and non-LND (nLND) groups (0.7% vs. 2.9%, P = 0.367). The median OS in the LND group was significantly longer (44 vs. 32 months, P = 0.045) and LND was identified as an independent protective factor for OS by multivariate analysis (HR 0.65, 95% CI 0.46–0.92, P = 0.014). Patients with the following characteristics were potential beneficiaries of LND: white, female, no/moderate fibrosis, tumor size > 5 cm, solitary tumor, and localized invasion (all P < 0.05). TNLE ≥ 6 had the greatest discriminatory power for identifying lymph node metastasis (area under the curve, 0.704, Youden index, 0.365, P = 0.002). Patients with pathologically confirmed lymph node metastasis are likely to benefit from adjuvant therapy (40 months vs. 4 months, P = 0.052). CONCLUSIONS: Advanced age (≥ 70 years) was not a contraindication for LND, which facilitates accurate nodal staging and guides postoperative management. Appropriately selected elderly populations could benefit from LND. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11605-023-05846-y. Springer US 2023-10-02 2023 /pmc/articles/PMC10661814/ /pubmed/37783911 http://dx.doi.org/10.1007/s11605-023-05846-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Lin, Qianyi
Chen, Jianjun
Li, Kangde
Yang, Junxing
Luo, Xiaofeng
Cai, Qi
Lin, Weihong
Peng, Guanjing
Chen, Dexiong
Qin, Chunhong
He, Tao
Wang, Zhenlong
Is Lymphadenectomy Reasonable for Elderly Intrahepatic Cholangiocarcinoma Patients?
title Is Lymphadenectomy Reasonable for Elderly Intrahepatic Cholangiocarcinoma Patients?
title_full Is Lymphadenectomy Reasonable for Elderly Intrahepatic Cholangiocarcinoma Patients?
title_fullStr Is Lymphadenectomy Reasonable for Elderly Intrahepatic Cholangiocarcinoma Patients?
title_full_unstemmed Is Lymphadenectomy Reasonable for Elderly Intrahepatic Cholangiocarcinoma Patients?
title_short Is Lymphadenectomy Reasonable for Elderly Intrahepatic Cholangiocarcinoma Patients?
title_sort is lymphadenectomy reasonable for elderly intrahepatic cholangiocarcinoma patients?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661814/
https://www.ncbi.nlm.nih.gov/pubmed/37783911
http://dx.doi.org/10.1007/s11605-023-05846-y
work_keys_str_mv AT linqianyi islymphadenectomyreasonableforelderlyintrahepaticcholangiocarcinomapatients
AT chenjianjun islymphadenectomyreasonableforelderlyintrahepaticcholangiocarcinomapatients
AT likangde islymphadenectomyreasonableforelderlyintrahepaticcholangiocarcinomapatients
AT yangjunxing islymphadenectomyreasonableforelderlyintrahepaticcholangiocarcinomapatients
AT luoxiaofeng islymphadenectomyreasonableforelderlyintrahepaticcholangiocarcinomapatients
AT caiqi islymphadenectomyreasonableforelderlyintrahepaticcholangiocarcinomapatients
AT linweihong islymphadenectomyreasonableforelderlyintrahepaticcholangiocarcinomapatients
AT pengguanjing islymphadenectomyreasonableforelderlyintrahepaticcholangiocarcinomapatients
AT chendexiong islymphadenectomyreasonableforelderlyintrahepaticcholangiocarcinomapatients
AT qinchunhong islymphadenectomyreasonableforelderlyintrahepaticcholangiocarcinomapatients
AT hetao islymphadenectomyreasonableforelderlyintrahepaticcholangiocarcinomapatients
AT wangzhenlong islymphadenectomyreasonableforelderlyintrahepaticcholangiocarcinomapatients